Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $12.5 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $12.5 million, down 13.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.8 million (down 13.52% YoY), and the FY2025 annual result was $53.7 million, down 12.25% from the prior year.
• Depreciation & Amortization (CF) eased to $12.5 million in Q1 2026 per MYGN's latest filing, from $12.6 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $19.4 million in Q1 2023 and troughed at $12.5 million in Q1 2026.
• A 5-year average of $14.2 million and a median of $14.1 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) declined 29.35% in 2022, then jumped 49.23% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.7 million in 2022, then increased by 10.22% to $15.1 million in 2023, then slipped by 1.99% to $14.8 million in 2024, then fell by 14.86% to $12.6 million in 2025, then decreased by 0.79% to $12.5 million in 2026.
• Business Quant data shows MYGN's Depreciation & Amortization (CF) at $12.5 million in Q1 2026, $12.6 million in Q4 2025, and $12.6 million in Q3 2025.